The hyperoxic toxicity can damage the intestinal barrier of newborn rats, resulting in impaired intestinal development and function[5].As a result, long-term oxygen therapy can cause nutritional absorption disorders and even restrict the growth and development of children. In this study, we have confirmed that ferroptosis plays a significant role in hyperoxia-induced injury of the intestinal tissue, both in vitro and in vivo. Additionally, we have discovered that hyperoxia activates Nrf2 to regulate ferroptosis and mediate inflammatory reactions via the COX-2/PGE2/EP2 pathway. These findings can serve as a new experimental basis for preventing neonatal organ injury resulting from hyperoxia treatment in clinical practice.
In this study, we developed a hyperoxia rat model by exposing newborn rats to hyperoxia on day 3, day 7, day 10, and day 14 after birth to investigate the mechanism of intestinal injury caused by hyperoxia. Excessive ROS can stimulate pathological redox signals leading to oxidative stress[30]. Cells develop their own antioxidant mechanisms, including several antioxidant enzymes such as the SOD enzyme family, glutathione peroxidase (GPX), and non-enzyme substances such as GSH to combat oxidative stress[31].Our results showed that compared to the control, SOD and GSH levels increased on day 3 and day 7, decreased significantly on day 10, and then increased again on the 14th day. Conversely, MDA, the end-product of lipid peroxidation, showed an opposite trend[32]. Therefore, we hypothesized that the early increase of GSH and SOD might be a response to oxidative stress induced by hyperoxia. As the exposure time to hyperoxia increased, the antioxidant capacity of the intestinal tissue of neonatal rats decreased, as evidenced by the reduction in GSH and SOD levels and the increase in MDA levels on the 10th day of hyperoxia. Additionally, hyperoxia led to the accumulation of ROS, causing oxidative stress. Mitochondria were identified as the primary source of intracellular ROS, and excessive ROS can lead to mitochondrial damage. Our findings indicate that hyperoxia causes a decrease in mitochondrial membrane potential, leading to oxidative stress and reduction of the cellular antioxidant capacity. This results in the accumulation of ROS in cells, leading to mitochondrial and cellular damage. These characteristics are also observed in ferroptosis, which leads us to speculate that ferroptosis may contribute to the intestinal oxidative damage induced by hyperoxia.
Ferroptosis is an iron and oxidation-dependent form of cell death, and iron is essential for the accumulation of lipid peroxide and the onset of ferroptosis[33]. The balance of iron metabolism is maintained through the input, output, and storage of iron ions[34]. Iron input proteins include transferrin, TFRC, and DMT1, while iron output proteins include ferroportin 1 (Fpn1)[35]. Currently, it is believed that the occurrence of ferroptosis is related to abnormalities in iron metabolism, such as GPX4 inactivation, cystine/glutamate reverse transport system (System Xc-) inhibition, and lipid peroxidation, ultimately leading to an imbalance in ROS homeostasis and cell death[36–37]. In both in vivo and in vitro experiments, we found that hyperoxia increased DMT1 and TFRC, and decreased Nrf2 targeting gene FTH1 as well as the antioxidant protein GPX4 and SLC7A11, indicating the occurrence of ferroptosis. Nrf2 plays a crucial role in maintaining normal redox homeostasis and in mediating other metabolic pathways, including protease balance, iron/heme metabolism, lipid metabolism, and cell apoptosis[38–39]. So Nrf2 was involved in regulating the iron transporter and iron storage proteins[40]. And Nrf2 could directly or indirectly regulate the expression and function of GPX4[41]. In this study, we used the Nrf2 agonist tBHQ and its inhibitor ML385 to up/down-regulate its expression, respectively. The results showed that up-regulation of Nrf2 in intestinal epithelial cells inhibited the occurrence of ferroptosis under hyperoxia and played a protective role during cell injury, while down-regulation of Nrf2 had the opposite effect. These results suggest that a lot of Nrf2 protected cells from damage by inhibiting ferroptosis in hyperoxia.
In ferroptosis, inflammatory mediators are produced by lipid peroxidation and AA metabolism, such as COX-2, which is also the key rate-limiting enzyme in the synthesis of PGs[42–43]. In this study, we detected COX-2 and its downstream molecules-EP2 and EP4, namely the two receptor subtypes of PGE2. We found that hyperoxia activated the COX-2/PGE2 pathway and up-regulated the expression of the pro-inflammatory factor TNF-α, suggesting that hyperoxia leads to ferroptosis in parallel with inflammatory damage in vivo and in vitro. In ferroptosis COX-2 is a key marker and increased significantly[44–45]. A recent study showed that anti-inflammatory treatment inhibited ferroptosis, and ferroptosis inhibitor Fer-1 inhibited COX-2, in other words, ferroptosis and inflammationmay also complement each other[46]. In this study Fer-1 reduced the expression of COX-2, EP4, and EP2, and reduced inflammation in intestinal epithelial cells in hyperoxia. Our findings were similar to a previous study in which Fer-1 decreased the level of ROS and alleviated inflammation[47]. So we suggest that in hyperoxia ferroptosis deteriorated oxidative damage and inflammation.
To confirm the role of the COX-2/PGE2/EP pathway in hyperoxia-induced intestinal epithelial cell inflammation, we first added the COX-2 inhibitor Celecoxib to the intestinal epithelial cells. As expected, COX-2 inhibition reduced the expression of downstream receptors EP2 and EP4, and partially inhibited the inflammation caused by hyperoxia in intestinal epithelial cells. Previous studies have shown that PGE2 causes acute inflammation by relaxing vascular smooth muscle cells through the EP2/EP4 signal pathway[48]. PGE2 also promotes Th1 cell differentiation, Th17 cell proliferation, and IL-22 production of Th22 cell in vitro through EP2 and EP4 receptors[49]. This shows that EP2 and EP4 receptors play a significant role in inflammation. To explore the specific downstream receptors, EP2 and EP4 were inhibited, respectively. Interestingly, while the addition of EP2 inhibitor TG4-155 successfully inhibited the expression of COX-2 and EP2 in intestinal epithelial cells and reduced the levels of inflammation-related factors TNF-α, IL-4 and IL-6, the addition of EP4 inhibitor had no significant effect. These results indicated that the continuous up-regulation of COX-2 during hyperoxia increased the level of PGE2, which promoted inflammation through the EP2 receptor rather than the EP4 receptor.